Skip to main content
SpringerLink
Log in

Neurodegenerative Diseases: from the First CNS Drugs to New Treatments in Discovery (A Review)

  • Published:
Russian Journal of Bioorganic Chemistry Aims and scope Submit manuscript

Abstract

Man has always sought to eradicate pathologies that affect the CNS (pain, anxiety, insomnia, euphoriants, psychedelic drugs, etc.). This obsession with finding new molecules that act on the CNS, has been considerably amplified by the increasingly frequent appearance of neurodegenerative diseases which affect human health. It is predicted that the world-wide prevalence of Alzheimer’s Disease dementia, will triple from its current 50 to 150 million by 2050. The first part of this manuscript is a brief history of the discovery of the first molecules acting on the CNS. The second part describes drugs that are actually prescribed for the treatment of AD, unfortunately, these drugs have only low effectiveness on the disease, or even no observable effects. The third part describes current advances in the field of therapy of CNS-related diseases. Three research directions are currently in development: research for new innovative “small molecules” or resulting from a repositioning of molecules having received marketing authorization; development of monoclonal antibodies for the treatment of neurodegenerative pathologies; development of specific treatments such as neurostimulation for the treatment of Parkinson’s disease; the last part of the manuscript is devoted to the Human Brain Connectome Project (HBCP), which aims to better understand the biological mechanisms of these neurodegenerative pathologies, and to help in the development of new treatments.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1.
Fig. 2.

Similar content being viewed by others

DATA AVAILABILITY

The data that support the findings of this study are available from the corresponding author upon reasonable request.

REFERENCES

  1. Hartog, F. and Jaccotet, P., L’Odyssée–Homère. La Découverte Editor. October 1992. ISBN: 10.2707112992.

  2. Meadway, C., George, S., and Braithwaite, R., Forensic Sci. Int., 1998, vol. 96, pp. 29–38. https://doi.org/10.1016/s0379-0738(98)00107-8

    Article  CAS  PubMed  Google Scholar 

  3. Goldworthy, A., The True Story of “Antony and Cleopatra.” Goldsworthy, A. Ed., UK: Yale’s University Press, 2010, Weidenfeld and Nicolson, p. 606. ASIN: B0043M64LA.

  4. Jouve, P.J., Shakespeare, Macbeth, Flammarion, Ed., 2006, p. 59. ISBN: 978-2-08-071295-0.

  5. Gulland, J.M. and Robinson, R., Constitution of Codeine and Thebaine. Mem. Proc. Manchester Lit. Philos. Soc, 1925, vol. 69, pp. 79–86.

    CAS  Google Scholar 

  6. Eliel, E.L., Wilen, S.H., and Mander, L.N., Stereochemistry of Organic Compounds, 1994, Wiley, Ed., New-York. ISBN: 0-471-01670-5.

  7. Mann, C.C. and Plummer, M.L., The Aspirin Wars: Money, Medicine, and 100 Years of Rampant Competition, Knopf, A.A., Ed., 1991, New York. ISBN: 978-0-394-57894-1.

  8. Goldberg, D.R., Chem. Heritage J., 2009, vol. 27, pp. 26–30.

    CAS  Google Scholar 

  9. Vane, J.R. and Botting, R.M., Thromb. Res., 2003, vol. 15, pp. 255–228. https://doi.org/10.1016/s0049-3848(03)00379-7

    Article  Google Scholar 

  10. Kraus, J.L., Psychology, 2014, vol. 5, pp. 365–368. https://doi.org/10.4236/psych.2014.55047

    Article  Google Scholar 

  11. Balon, R., Starcevic, V., Silberman, E., Cosci, F., Dubovsky, S., Fava, G.A., Nardi, A.E., Rickels, K., Salzman, C., Shader, R.I., and Sonino, N., Revista Brasileira de Psiquiatria, 2020, vol. 42, pp. 243–244. https://doi.org/10.1590/1516-4446-2019-0773

  12. Washton, A.M. and Zweben, J.E., Treating Alcohol and Drug Problems in Psychotherapy Practice Doing What Works, New-York: Guilford Publications Ed., 2011, p. 47. ISBN: 9781462504381.

  13. Diazepam-Drug Usage Statistics, United States, ClinCalc Drugstats Database, 2013–2020. https://clincalc.com/DrugStats/Drugs/Diazepam

  14. Guerchet, M., Number of People with Dementia Worldwide, 2020, Alzheimer’s Disease International (ADI). https://www.alzint.org/

  15. FDA Approves First Drug to Treat Agitation Symptoms Associated with Dementia Due to Alzheimer’s Disease. U.S. Food and Drug Administration (FDA), 2023. https://www.fda.gov/

  16. Huang, L.K., Chao, S.P., and Hu, C.J., J. Biomed. Sci., 2020, vol. 27, p. 18. https://doi.org/10.1186/s12929-019-0609

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Cummings, G.L., Morstof, T., and Zhong, K., Alzheimer’s Res. Ther., 2014, vol. 6, p. 37. https://doi.org/10.1186/alzrt269

    Article  Google Scholar 

  18. Hoelder, S., Clarke, P.A., and Workman, P., Mol. Oncol., 2012, vol. 6, pp. 155–176. https://doi.org/10.1016/J.molonc

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Pray, L.A., Nat. Education, 2008, vol. 1, p. 37. https://www.nature.com/

    Google Scholar 

  20. Cummings, J., Lee, G., Nahed, P., Nojoo Kambar, M.E.Z., Zhong, K., Fonseca, J., and Taghva, K., Alzheimer’s Dement., 2022, vol. 8, p. e12295. https://doi.org/10.1002/trc2.12295

  21. Novel Drug Approvals for 2021, U.S. Food and Drug Administration, 2021. https://www.fda.gov/

  22. Cummings, J., Lee, G., Ritter, A., Sabbagh, M., and Zhong, K., Alzheimer’s Dement., 2020, vol. 6, p. e12050. https://doi.org/10.1002/trc2.12050

  23. Cummings, J., Lee, G., Zhong, K., Fonseca, J., and Taghva, K., Alzheimer’s Dement., 2021, vol. 7, p. e12179. https://doi.org/10.1002/trc2.12179

  24. Grossberg, G.T., Kohegyi, E., Mergel, V. Josiassen, M.K., Meulien, D., Hobart, M., Slomkowski, M., Baker, R.A., McQuade, R.D., and Cummings, J.L., Am. J. Geriatr. Psychiatry, 2020, vol. 4, pp. 383–400. https://doi.org/10.1016/j.jagp.2019.09.009

    Article  Google Scholar 

  25. Herring, W.J., Ceesay, P., Snyder, E., Bliwise, D., Budd, K., Hutzelmann, J., Stevens, J., Lines, C., and Michelson, D., Alzheimers Dement., 2020, vol. 16, pp. 541–551. https://doi.org/10.1002/alz.12035

    Article  PubMed  Google Scholar 

  26. Walsh, S., Merrick, R., Milne, R., and Brayne, C., BMJ, 2021, Article ID: 374n1682. https://doi.org/10.1136/bmj.n1682

  27. Sevigny, J., Chiao, P., Bussière, T., Weinreb, P.H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., O’Gorman, J., Qian, F., Arastu, M., Li, M., Chollate, S., Brennan, M.S., Quintero-Monzon, O., Scannevin, R.H., Arnold, H.M., Engber, T., Rhodes, K., Ferrero, J., Hang, Y., Mikulskis, A., Grimm, J., Hock, C., Nitsch, R.M., and Sandrock, A., Nature, 2016, vol. 537, pp. 50–56. https://doi.org/10.1038/nature19323

  28. Abyadeh, M., Gupta, V., Gupta, V., Chitranshi, N., Wu, Y., Amirkhani, A., Meyfour, A., Sheriff, S., Shen, T., Dhiman, K., Salekdeh, G.H., Haynes, P.A., Graham, S.L., and Mirzaei, M., Aging Dis., 2021, vol. 12, pp. 1964–1976.

  29. Toyn, J., Exp. Rev. Clin. Pharmacol., 2025, vol. 8, p. 269. https://doi.org/10.1586/17512433.2015.1034690

  30. Drug Approval Package: Leqembi, U.S. Food and Drug Administration (FDA), 2023.

  31. Lecanemab Summary Review. Center for Drug Evaluation and Research (CDER), U.S. Food and Drug Administration (FDA), 2023.

  32. FDA Grants Accelerated Approval for Alzheimer’s Disease Treatment, U.S. Food and Drug Administration (FDA), 2023.

  33. FDA Converts Novel Alzheimer’s Disease Treatment to Traditional Approval. U.S. Food and Drug Administration (FDA), 2023.

  34. Mulnard, A., Nat. Rev. Drug Discov., 2021, vol. 20, p. 888. https://doi.org/10.1038/d41573-021-00187-4

    Article  CAS  Google Scholar 

  35. Mulnard, A., Nat. Rev. Drug Discov., 2021, vol. 20, pp. 3–5. https://doi.org/10.1038/d41573-020-00217-7

    Article  CAS  Google Scholar 

  36. World Health Organization (WHO)–Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx). https://vizhub.healthdata.org/gbd-results/

  37. Benabid, A.L., Curr. Opin. Neurobiol., 2003, vol. 13, pp. 696–706. https://doi.org/10.1016/j.conb.2003.11.001

    Article  CAS  PubMed  Google Scholar 

  38. Williams, R., Alim-Louis Benabid: Stimulation and Serendipity, 2010. https://scirp.org/

  39. Benabid, A.L., Chabardes, S., Mitrofanis, J., and Pollak, P., Lancet Neurol., 2009, vol. 8, pp. 67–81. https://doi.org/10.1016/S1474-4422(08)70291-6

    Article  PubMed  Google Scholar 

  40. National Cancer Institute. Cancer Therapies, NIH, 2012.

  41. Azevedo, F.A., Carvalho, L.R, Grinberg, L.T., Farfel, J.M., Ferretti, R.E.L., Leite, R.E.P., Filho, W.J., Lent, R., and Herculano-Houzel, S., J. Comp. Neurol., 2009, vol. 513, pp. 532–541. https://doi.org/10.1002/cne.21974

    Article  PubMed  Google Scholar 

  42. Herculano-Houzel, S., Proc. Natl. Acad. Sci. USA, 2012, vol. 109, pp. 10661–10668. https://doi.org/10.1073/pnas.1201895109

  43. Elam, J.S, Glasser, M., Harms, M., Sotiropoulos, S.N., Andersson, J.L.R., Burgess, G.C., Curtiss, S.W., Oostenveld, R., Larson-Prior, L.J., Schoffelen, J.-M., Hodge, M.R., Cler, E.A., Marcus, D.M., Barch, D.M., Yacoub, E., Smith, S.M., Ugurbil, K., and Van Essen, D.C., NeuroImage, 2021, vol. 244, Article ID: 118543. https://doi.org/10.1016/j.neuroimage.2021.118543

  44. Mashey, J., ACM Queue, 2006, vol. 4, pp. 85–94. https://doi.org/10.1145/1165754.1165766

    Article  Google Scholar 

  45. Haier, R., The Neuroscience of Intelligence, Cambridge University Press, 2016, pp. 18–19. ISBN: 9781107461437.

  46. Herculano-Houzel, S., Front Hum. Neurosci., 2009, vol. 3, p. 31. https://doi.org/10.3389/neuro.09.031.2009

    Article  PubMed  PubMed Central  Google Scholar 

  47. Budd Haeberlein, S., Aisen, P.S., Barkhof, F., Chalkias, S., Chen, T., Cohen, S., Dent, G., Hansson, O., Harrison, K., von Hehn, C., Iwatsubo, T., Mallinckrodt, C., Mummery, C.J., Muralidharan, K.K., Nestorov, I., Nisenbaum, L., Rajagovindan, R., Skordos, L., Tian, Y., van Dyck, C.H., Vellas, B., Wu, S., Zhu, Y., and Sandrock, A., Prev. Alzheimer’s Dis., 2022, vol. 9, pp. 197–210. https://doi.org/10.14283/jpad.2022.30

    Article  CAS  Google Scholar 

  48. Swanson, C.J., Zhang, Y., Dhadda, S., Wang, J., Kaplow, J., Lai, R.Y.K., Lannfelt, L., Bradley, H., Rabe, M., Koyama, A., Reyderman, L., Berry, D.A., Berry, S., Gordon, R., Kramer, L.D., and Cummings, J.L., Alzheimer’s Res. Ther., 2021, vol. 13, pp. 80–94. https://doi.org/10.1186/s13195-021-00813-8

    Article  CAS  Google Scholar 

  49. van Dyck, C.H., Swanson, C.J., Aisen, P., Bateman, R.J., Chen, C., Gee, M., Kanekiyo, M., Li, D., Reyderman, L., Cohen, S., Froelich, L., Katayama, S., Sabbagh, M., Vellas, B., Watson, D., Dhadda, S., Irizarry, M., Kramer, L.D., and Iwatsubo, T., New Engl. J. Med., 2023, vol. 388, pp. 9–21. https://doi.org/10.1056/nejmoa2212948

    Article  CAS  PubMed  Google Scholar 

Download references

ACKNOWLEDGMENTS

Dr. Kodjabachian, director is greatly acknowledged for facilities offered.

Funding

Institut de Biologie du Développement de Marseille (IBDM). Aix-Marseille University and CNRS UMR 7288 France are greatly acknowledged for financial support.

Author information

Authors and Affiliations

  1. Institut de Biologie du Développement de Marseille, UMR 7288, CNRS, Aix-Marseille University, Marseille, 13888, Cedex, France

    Jean-Louis Kraus

Authors
  1. Jean-Louis Kraus
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The author J-LK wrote this article.

Corresponding author

Correspondence to Jean-Louis Kraus.

Ethics declarations

This article does not contain any studies involving patients or animals as test objects.

Informed consent was not required for this article. No conflict of interest was declared by the author.

Additional information

Publisher's Note. Pleiades Publishing remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Abbreviations: AD, Alzheimer disease; AI, Artificial intelligence; CNS, Central nervous system; PGs, Prostaglandins; COX, Cyclooxygenase; BDZ, Benzodiazepine; FDA, Federal drug agency; IQ, Intelligence quotient.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kraus, JL. Neurodegenerative Diseases: from the First CNS Drugs to New Treatments in Discovery (A Review). Russ J Bioorg Chem 50, 273–281 (2024). https://doi.org/10.1134/S1068162024020171

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1134/S1068162024020171

Keywords:

Search

Navigation